NO20015859L - A- <beta> peptide preparations and methods for their preparation - Google Patents

A- <beta> peptide preparations and methods for their preparation

Info

Publication number: NO20015859L
Authority: NO; Norway
Prior art keywords: beta; preparation; methods; peptide preparations; preparations
Prior art date: 1999-06-01

Application number

NO20015859A

Other languages

Norwegian (no)

Other versions

NO20015859D0 (en

Inventor

Pamela Hirtzer

Naina Patel

Original Assignee

Neuralab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2001-11-30

Publication date

2002-02-01

2001-11-30 Application filed by Neuralab Ltd filed Critical Neuralab Ltd

2001-11-30 Publication of NO20015859D0 publication Critical patent/NO20015859D0/en

2002-02-01 Publication of NO20015859L publication Critical patent/NO20015859L/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Zoology (AREA)
Mycology (AREA)
Psychiatry (AREA)
Marine Sciences & Fisheries (AREA)
Hospice & Palliative Care (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20015859A 1999-06-01 2001-11-30 A- <beta> peptide preparations and methods for their preparation NO20015859L (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13704799P	1999-06-01	1999-06-01
PCT/US2000/015302 WO2000072870A1 (en)	1999-06-01	2000-06-01	Compositions of a-beta peptide and processes for producing same

Publications (2)

Publication Number	Publication Date
NO20015859D0 NO20015859D0 (en)	2001-11-30
NO20015859L true NO20015859L (en)	2002-02-01

Family

ID=22475602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015859A NO20015859L (en)	1999-06-01	2001-11-30	A- <beta> peptide preparations and methods for their preparation

Country Status (25)

Country	Link
EP (1)	EP1181040A1 (en)
JP (1)	JP2003519620A (en)
KR (1)	KR20020016813A (en)
CN (1)	CN1353615A (en)
AR (1)	AR024558A1 (en)
AU (1)	AU5726100A (en)
BG (1)	BG106249A (en)
BR (1)	BR0011251A (en)
CA (1)	CA2374897A1 (en)
CZ (1)	CZ20014150A3 (en)
EE (1)	EE200100649A (en)
HK (1)	HK1045938A1 (en)
HR (1)	HRP20010901A2 (en)
IL (1)	IL146575A0 (en)
IS (1)	IS6182A (en)
MX (1)	MXPA01012355A (en)
NO (1)	NO20015859L (en)
NZ (1)	NZ515744A (en)
PE (1)	PE20010212A1 (en)
PL (1)	PL352575A1 (en)
RU (1)	RU2001135800A (en)
SK (1)	SK17012001A3 (en)
TR (1)	TR200103476T2 (en)
WO (1)	WO2000072870A1 (en)
ZA (1)	ZA200109704B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
WO2002003911A2 (en)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention and treatment of alzheimer's disease
AU1225702A (en) *	2000-09-19	2002-04-02	Evotec Neurosciences Gmbh	Methods and compounds for treating brain amyloidosis
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en)	2000-12-06	2002-07-02	Wyeth Corp	HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid β (1-42) oligomers, process for their preparation and their use
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (en)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
TW200636066A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Humanized amyloid beta antibodies for use in improving cognition
RU2442793C2 (en)	2005-11-30	2012-02-20	Эбботт Лэборетриз	ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES
KR101434935B1 (en)	2005-11-30	2014-10-01	애브비 인코포레이티드	Monoclonal Antibodies to Amyloid Beta Proteins and Their Uses
MY169492A (en)	2006-03-23	2019-04-15	Bioarctic Neuroscience Ab	Improved protofibril selective antibodies and the use thereof
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
SI2182983T1 (en)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	Immunotherapy regimes dependent on apoe status
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
MX360403B (en)	2010-04-15	2018-10-31	Abbvie Inc	Amyloid-beta binding proteins.
EP2603524A1 (en)	2010-08-14	2013-06-19	AbbVie Inc.	Amyloid-beta binding proteins
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
MA53887A (en)	2014-07-10	2021-10-27	Bioarctic Ab	ENHANCED PROTOFIBRILL A-BETA BINDING ANTIBODY
US11413351B2 (en)	2016-01-08	2022-08-16	Ascendis Pharma Growth Disorders A/S	CNP prodrugs with carrier attachment at the ring moiety
IL318754A (en)	2016-01-08	2025-04-01	Ascendis Pharma Growth Disorders As	Controlled-release cnp agonists with low initial npr-b activity
IL259659B (en)	2016-01-08	2022-08-01	Ascendis Pharma Growth Disorders As	Controlled-release cnp agonists with increased nep stability
CN114957438B (en) *	2022-06-28	2024-04-02	福建亿彤生物科技有限公司	Human Aβ1-42 antigenic determinant polypeptide for detecting Alzheimer's disease and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE153534T1 (en) *	1990-04-27	1997-06-15	John Mcmichael	METHOD AND COMPOSITION FOR TREATING CNS DISEASES CAUSED BY ABNORMAL BETA-AMYLOID PROTEIN
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

2000
- 2000-05-31 AR ARP000102690A patent/AR024558A1/en unknown
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/en not_active Application Discontinuation
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/en not_active Application Discontinuation
- 2000-06-01 CN CN00808374A patent/CN1353615A/en active Pending
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/en not_active Withdrawn
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/en unknown
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 EE EEP200100649A patent/EE200100649A/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/en unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/en unknown
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/en unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/en not_active Application Discontinuation
- 2000-06-01 IL IL14657500A patent/IL146575A0/en unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/en not_active Application Discontinuation
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/en unknown
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/en unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/en not_active Application Discontinuation
- 2001-12-04 HR HR20010901A patent/HRP20010901A2/en not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/en unknown
2002
- 2002-08-23 HK HK02106241.2A patent/HK1045938A1/en unknown

Also Published As

Publication number	Publication date
IS6182A (en)	2001-11-29
ZA200109704B (en)	2003-02-26
WO2000072870A1 (en)	2000-12-07
SK17012001A3 (en)	2002-06-04
PE20010212A1 (en)	2001-02-22
CA2374897A1 (en)	2000-12-07
AU5726100A (en)	2000-12-18
HRP20010901A2 (en)	2003-04-30
IL146575A0 (en)	2002-07-25
EP1181040A1 (en)	2002-02-27
RU2001135800A (en)	2003-08-20
PL352575A1 (en)	2003-08-25
BR0011251A (en)	2002-03-05
AR024558A1 (en)	2002-10-16
HK1045938A1 (en)	2002-12-20
JP2003519620A (en)	2003-06-24
MXPA01012355A (en)	2003-06-24
NO20015859D0 (en)	2001-11-30
BG106249A (en)	2002-08-30
CZ20014150A3 (en)	2002-05-15
TR200103476T2 (en)	2002-04-22
CN1353615A (en)	2002-06-12
KR20020016813A (en)	2002-03-06
NZ515744A (en)	2004-04-30
EE200100649A (en)	2003-02-17

Publication	Publication Date	Title
NO20015859L (en)	2002-02-01	A- <beta> peptide preparations and methods for their preparation
NO992779D0 (en)	1999-06-08	OB fusion protein preparations and methods for their preparation
NO20021401D0 (en)	2002-03-20	Conazoline compounds and pharmaceutical preparations containing such compounds
IS6040A (en)	2001-08-07	Valdekoxib preparations
NO20014220L (en)	1998-11-09	<Kappa-agonist compounds and pharmaceutical preparations thereof
IS5953A (en)	2001-05-25	Pharmaceutical preparations from microplated eplerenones
DK1210113T3 (en)	2006-07-03	Combined vaccine preparations
EE200200038A (en)	2003-04-15	Preserved pharmaceutical preparations
NO20016277D0 (en)	2001-12-20	Systems and methods for aerolizing pharmaceutical formulations
PT1177178E (en)	2005-05-31	SUBSTITUTED HETERICYLIC BENZIMIDAZOES, THEIR PREPARATION AND APPLICATION
DK0988861T3 (en)	2004-04-19	Stabilized protein preparations
NO20021949L (en)	2002-04-25	New hormone preparations and their use
AU5744200A (en)	2001-01-09	Human transport proteins
PT1228039E (en)	2004-09-30	N-GUANIDINOALQUILAMIDES ITS PREPARATION ITS USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
DK1178799T3 (en)	2003-12-22	Gastroprotected microgranules, method of obtaining same and pharmaceutical preparations
DE69926012D1 (en)	2005-08-04	PHARMACEUTICAL PREPARATIONS
AU4483500A (en)	2000-11-10	Human membrane-associated proteins
DE69906934D1 (en)	2003-05-22	PHARMACEUTICAL PREPARATIONS
NO20020777L (en)	2002-02-15	Pharmaceutical preparations containing derivatives and process for their preparation
DK1192163T3 (en)	2003-12-08	Dithiepino [6,5-b] pyrines, related preparations and methods
DK1183241T3 (en)	2004-01-19	Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising these
NO985572L (en)	1999-01-26	Substituted amidinobenzene derivatives and medical preparations thereof
DE50009295D1 (en)	2005-02-24	NETWORK-FREE PREPARATIONS
FR2802775B1 (en)	2005-06-03	ICE AND AEREES PREPARATIONS
FI974610A0 (en)	1997-12-23	Pharmaceutical preparations in gelform

Legal Events

Date	Code	Title	Description
2005-06-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application